Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 100mg;   - tablet - 100 mg - active: clozapine 100mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 200mg;   - tablet - 200 mg - active: clozapine 200mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - clozapine 25mg;   - tablet - 25 mg - active: clozapine 25mg   excipient: lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water sodium starch glycolate - the use of clozapine is indicated in the treatment of resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to or intolerant of classical antipsychotics. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two marketed antipsychotics prescribed for adequate durations. intolerance is defined as the impossibility of achieving adequate clinical benefit with classical antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).